-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Neutral on Y-mAbs Therapeutics, Lowers Price Target to $12

Benzinga·03/05/2025 18:08:58
Listen to the news
B of A Securities analyst Alec Stranahan maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Neutral and lowers the price target from $14 to $12.